Loading
A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting.
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) is a phase 3 interventional study registered as NCT07190248, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007). Planned enrolment is 675 participants (estimated). The study started in 2025-10-08 and primary completion is expected in 2029-12-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/